2026-05-22T11:08:16Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/200252024-11-28T21:09:04Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Cassinello, J.
author
Climent, M. A.
author
Gonzalez Del Alba, Aranzazu
author
Mellado, B.
author
Virizuela, J. A.
2024-07-03T11:09:40Z
2024-07-03T11:09:40Z
2014-12
Cassinello J, Climent MA, Gonzalez Del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014 Dec;16(12):1060-6. Epub 2014 Oct 16.
10.1007/s12094-014-1225-3
1699-3055
1699-048X
Clinical & Translational Oncology
http://hdl.handle.net/20.500.13003/11050
25319721
L600179806
2-s2.0-84919419308
http://hdl.handle.net/20.500.12105/20025
345397300006
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required.
eng
Androgen deprivation treatment
Castration-resistant prostate cancer
Docetaxel
Cabacitaxel
Abiraterone
Enzalutamide
Radium 223
SEOM Clinical guidelines for the treatment of metastatic prostate cancer
research article